NCT03719326 2024-05-24A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesArcus Biosciences, Inc.Phase 1 Completed35 enrolled